Literature DB >> 1660194

Human papillomavirus type 16 E6 proteins with glycine substitution for cysteine in the metal-binding motif.

T Kanda1, S Watanabe, S Zanma, H Sato, A Furuno, K Yoshiike.   

Abstract

The human papillomavirus type 16 (HPV 16) E6 is a 151 amino acid protein containing four metal-binding motifs, Cys-X-X-Cys. We constructed and characterized three mutants with Gly substitutions for Cys within the motif; for Cys-66, for Cys-136, and for both, respectively. Zinc binding to bacterially expressed E6 was markedly reduced by the substitution for Cys-66, but DNA binding was unaffected by any of these mutations. Immunofluorescence staining showed that, whereas the E6 expressed in monkey COS-1 cells appeared mostly nuclear, the Cys-66 mutant appeared cytoplasmic. Subcellular fractionation followed by immunoprecipitation showed that the E6 in COS-1 cells was located in the membrane, nuclear, and nuclear-wash fractions, but not in the soluble cytoplasmic fraction, and that the nuclear Cys-66 protein was markedly reduced. The mutant proteins in COS-1 cells appeared to be less stable than the wild type, because the immunofluorescent cells were fewer and because the E6 bands in autoradiograms were less dense. The substitution mutants lost their capacity to enhance HPV 16 E7 transformation of rat 3Y1 cells. The data indicate that Cys-66 plays a crucial role for zinc binding and nuclear localization of E6 and that both Cys-66 and Cys-136 are required for a stable or functional structure of E6.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660194     DOI: 10.1016/0042-6822(91)90523-e

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16.

Authors:  L Sherman; R Schlegel
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

2.  Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR.

Authors:  Shoji Nagao; Mitsuo Yoshinouchi; Yasunari Miyagi; Atsushi Hongo; Junichi Kodama; Sachio Itoh; Takafumi Kudo
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 3.  Mechanisms of genome propagation and helper exploitation by satellite phage P4.

Authors:  B H Lindqvist; G Dehò; R Calendar
Journal:  Microbiol Rev       Date:  1993-09

Review 4.  Regulation of apoptosis by the papillomavirus E6 oncogene.

Authors:  Ting-Ting Li; Li-Na Zhao; Zhi-Guo Liu; Ying Han; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

5.  Transforming properties of the cottontail rabbit papillomavirus oncoproteins Le6 and SE6 and of the E8 protein.

Authors:  J B Harry; F O Wettstein
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Human papillomavirus type 16 E2 and E6 are RNA-binding proteins and inhibit in vitro splicing of pre-mRNAs with suboptimal splice sites.

Authors:  Sohrab Bodaghi; Rong Jia; Zhi-Ming Zheng
Journal:  Virology       Date:  2009-02-01       Impact factor: 3.616

Review 7.  Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses.

Authors:  Zhi-Ming Zheng
Journal:  Int J Biol Sci       Date:  2010-12-01       Impact factor: 6.580

8.  Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins.

Authors:  Ewa Krawczyk; Frank A Suprynowicz; Xuefeng Liu; Yuhai Dai; Dan P Hartmann; John Hanover; Richard Schlegel
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

9.  Nuclear entry of high-risk human papillomavirus type 16 E6 oncoprotein occurs via several pathways.

Authors:  Lucia G Le Roux; Junona Moroianu
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest.

Authors:  S A Foster; G W Demers; B G Etscheid; D A Galloway
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.